DOJ Compound Pharmacy Fraud Investigations in New York

Compound pharmacies can serve an important purpose when patients need medications that are not commercially available in an appropriate form. But when compounded prescriptions are tied to unnecessary treatment, referral payments, or unusually high reimbursements, federal investigators may look beyond ordinary billing concerns.

For New York pharmacy owners, pharmacists, and healthcare providers, understanding what can turn legitimate compounding into an alleged healthcare fraud scheme is important.

Why is the DOJ Looking at Compound Pharmacies?

Federal prosecutors have increasingly focused on compounded medications in healthcare fraud cases because some compounded drugs can generate substantially higher reimbursements than standard medications.

Investigators may ask whether financial incentives influenced decisions to prescribe, dispense, or promote particular compounded medications.

Some of the issues investigators may examine include:

• Whether the medications prescribed were medically necessary for individual patients
• If prescriptions were generated through improper referral arrangements
• How marketers were compensated, including whether payments were tied to prescription volume
• Whether providers received financial incentives for directing prescriptions to a particular pharmacy
• If submitted claims accurately reflected the medications prescribed and dispensed
• Whether reimbursement was connected to an intentional scheme

The Main Avenue Pharmacy Fraud Case

A recent federal case involving a New Jersey pharmacy illustrates the type of conduct that can attract the DOJ’s attention.

In April 2026, former Main Avenue Pharmacy president Adam Brosius was sentenced to 24 months in prison for his role in a $33 million healthcare fraud and kickback scheme involving compounded medications.

According to the U.S. Department of Justice, the pharmacy filled prescriptions for compounded medications, including scar creams, pain creams, migraine medications, and vitamins. Prosecutors alleged that the medications were medically unnecessary and that prescription pads containing particular formulas were distributed to marketers.

The marketers allegedly provided those prescriptions to telemedicine companies and physicians with whom they had financial arrangements.

According to the DOJ, Main Avenue Pharmacy received approximately $33 million in reimbursement for compounded medications, including more than $5.8 million from TRICARE. Brosius was ordered to pay $33 million in restitution and forfeit $27 million.

When Can a Pharmacy Arrangement Become a Fraud Investigation?

Federal prosecutors may examine arrangements involving:

• Pharmacies and telemedicine companies
• Payments tied to prescription volume
• Pharmacies and prescribing physicians
• Compensation based on reimbursement
• Pharmacies and marketing companies
• High-dollar compounded medications promoted to patients

These arrangements can draw additional scrutiny when the financial incentive appears tied to the number or value of prescriptions generated.

Medical Necessity Can Become a Federal Issue

Medical necessity may also become a significant part of a compound pharmacy investigation.

Federal investigators can compare prescriptions against patient records and ask whether the treatment was appropriate for the particular patient. Questions may include:

• Was there a documented medical reason for the compounded medication?
• Did the patient actually receive the medication?
• Did the prescription reflect the patient’s condition?
• Was the same high-reimbursement medication routinely prescribed to large numbers of patients?
• Did financial considerations influence the prescribing decision?

Why New York Pharmacies May Face Federal Scrutiny

New York pharmacies may have relationships with patients, prescribers, telemedicine companies, and marketers nationwide. That means an investigation does not necessarily remain limited to the pharmacy’s immediate billing practices.

Federal investigators may review:

• Prescription and patient records
• Billing and reimbursement data
• Contracts with marketers or other businesses
• Communications with prescribing providers
• Financial transactions
• Internal pharmacy policies and communications

Fight Healthcare Fraud Allegations with Our Team

A federal investigation into compounded medications can involve more than a dispute over whether a particular claim was reimbursable.

If federal investigators are examining your New York pharmacy’s compounded-medication prescriptions, billing, or business relationships, contact Peter Katz at (609) 849-3179.